By:
www.cbsnews.com
Trying to shame an overweight or obese person into losing weight won’t motivate them to do so, and may even raise their risk for heart disease and other health problems, a new study suggests.
The more self-blame and devalued that people said they felt when stigmatized, the more likely they were to have health problems that could lead to heart disease, said study leader Rebecca Pearl. She’s an assistant professor of psychology at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia.
The findings suggest that weight stigma and fat shaming “go much deeper than the inappropriate remarks or hurt feelings,” said Dr. Rebecca Puhl, deputy director of the University of Connecticut Rudd Center for Food Policy & Obesity. She co-wrote a commentary that accompanied the study.
The study authors said obese people are often viewed as lazy, lacking willpower, incompetent, unattractive, and to blame for their excess weight.
This leaves them feeling stigmatized. Previous research has linked feeling stigmatized about weight to weight gain and emotional distress. The new study suggests it’s not just the stigmatizing, but also the level of a person’s reaction to fat-shaming that can impair health.
The new research wasn’t designed to prove a cause-and-effect link, however.
The study included 159 obese adults. The researchers asked them how much they devalued and blamed themselves when they were stigmatized for their weight. The researchers also looked to see how often a condition called metabolic syndrome had been diagnosed among these adults.
Metabolic syndrome is a cluster of risk factors, including high blood pressure, high triglycerides (a type of blood fat) and a large waist circumference. These risk factors are linked with higher risks of heart disease, type 2 diabetes and other health problems.
In all, 51 of the men and women met the criteria for metabolic syndrome, Pearl said. Those with higher levels of devaluation and self-blame were about 46 percent more likely to have metabolic syndrome.
When the researchers looked at those reporting the highest levels of internalizing devaluation and self-blame compared with the lowest group, the highest group had three times the risk of metabolic syndrome as those in the lowest.
The study team also found that those with the highest levels of feeling devalued were six times as likely to have high triglycerides.
The findings lend support to previous research, said commentary co-author Dr. Scott Kahan. He’s director of the National Center for Weight and Wellness in Washington, D.C.
“Numerous studies have shown that experiencing weight stigma increases stress hormones, blood pressure, inflammation and ultimately increases the risk of several diseases, including diabetes and heart disease,” Kahan said.
Weight stigma has also been linked with premature death, he said, as well as binge eating and weight gain.
The new research, he said, suggests that “experiencing weight stigma is bad, but worse appears to be internalizing weight stigma.”
“For people who have been targets of weight stigmatization, it is important for them to not add injury to insult by further self-stigmatizing themselves,” Kahan said. More needs to be learned about the complexities of obesity, he added, so people will realize it’s a complex health issue, not a willpower issue.
Puhl urged people to try to avoid self-blame. “Try to view the stigmatizing encounter as the other person’s problem instead of internalizing or blaming yourself,” she said. Everyone deserves respect, she added.
Loved ones should avoid blaming or criticizing friends or family struggling with weight -- it does not motivate weight loss, Puhl added.
The research was published Jan. 30 in the journal Obesity.
Source:
http://www.cbsnews.com/news/fat-shaming-can-lead-to-host-of-health-problems/
Isotretinoin scored 85 +/- 10% improvement compared with the baseline, whereas tetracyclines and cyproterone acetate plus ethinyloestradiol were less effective (54 +/- 3% versus 65 +/- 4% improvement compared with baseline, respectively). Moreover, studies suggested that isotretinoin reduces the risk of acne relapse in the few studies that included a follow-up period. A number of restrictions limit the general use of these drugs as monotherapy, e.g., potential teratogenicity. There is a continued need for effective drugs for the therapy of acne, although judicious combined use of existing topical and systemic therapies offers great relief to many patients. In addition, methodological problems in previous studies prevent adequate synthesis of existing knowledge within the framework of evidence-based medicine. There is therefore a demand for future standardisation of further acne studies to enable direct comparison of different treatment efficacies.
